Medical Management for 70-Year-Old Male with Abnormal ABI Suggesting PAD
Start single antiplatelet therapy with either clopidogrel 75 mg daily or aspirin 75-160 mg daily, initiate high-intensity statin therapy, and enroll in supervised exercise therapy for at least 3 months before considering any revascularization. 1, 2
Antiplatelet Therapy
Single antiplatelet therapy is the cornerstone of treatment for symptomatic PAD to reduce major adverse cardiovascular events (MACE). 1, 2
- Clopidogrel 75 mg daily is preferred over aspirin based on the CAPRIE trial showing superior efficacy with similar bleeding rates 1
- Alternatively, aspirin 75-160 mg daily is acceptable 2
- Do NOT use dual antiplatelet therapy (DAPT) long-term unless the patient has undergone recent revascularization (within 1-6 months) 1, 2
- Ticagrelor is not routinely recommended 2
Consider Adding Low-Dose Rivaroxaban
If the patient is NOT at high risk for bleeding, add rivaroxaban 2.5 mg twice daily to low-dose aspirin to reduce both cardiovascular and limb events. 1 The COMPASS trial demonstrated this combination reduces MACE and major adverse limb events (MALE) in symptomatic PAD, though it increases major bleeding risk. This is a Class 1 recommendation with Level A evidence. 1
Lipid Management
Initiate high-intensity statin therapy immediately regardless of baseline cholesterol levels. 3, 4
- Consider adding a PCSK9 inhibitor if LDL remains elevated on maximally tolerated statin therapy 4
- Target aggressive cholesterol lowering to reduce cardiovascular events 3
Blood Pressure Control
Target blood pressure <130/80 mmHg using antihypertensive medications. 3
- ACE inhibitors are preferred as first-line agents 5
Diabetes Management (if applicable)
If this patient has diabetes:
- Start an SGLT2 inhibitor with proven cardiovascular benefit to reduce cardiovascular events, independent of HbA1c targets 2, 3
- Add a GLP-1 receptor agonist (such as semaglutide) for additional cardiovascular protection 2, 3
- Target HbA1c <7% (53 mmol/mol) while avoiding hypoglycemia 2
- Prioritize glucose-lowering agents with proven cardiovascular benefits 2
Exercise Therapy
Supervised exercise therapy (SET) is mandatory and equally important as medications. 1, 2, 6
- Prescribe SET 3-5 days per week for at least 30 minutes per session 6
- Continue for minimum 12 weeks 6
- This is a Class I, Level A recommendation 2, 6
- If supervised programs are unavailable, structured home-based walking is an acceptable alternative (Class IIa) 6
- Exercise should involve walking to near-maximal claudication pain, resting, then resuming 6
Additional Pharmacotherapy
Consider cilostazol 100 mg twice daily to improve walking distance and claudication symptoms (Class I, Level A recommendation). 6
What NOT to Do
- Do NOT use full-intensity oral anticoagulation (warfarin or therapeutic-dose DOACs) unless there is another indication like atrial fibrillation—this may cause harm 1, 2
- Do NOT perform revascularization at this stage unless the patient has critical limb-threatening ischemia or persistent symptoms after 3 months of optimal medical therapy and exercise 2
- Do NOT use vorapaxar—benefit is uncertain with increased bleeding risk 1
Follow-Up
Schedule follow-up at least annually to assess:
- Clinical and functional status
- Medication adherence
- Limb symptoms
- Cardiovascular risk factor control
- Consider duplex ultrasound as needed 2
Critical Pitfall to Avoid
The most common error is proceeding directly to revascularization without an adequate trial of medical therapy and exercise. Revascularization should be reserved only for those with persistent disabling symptoms after 3 months of optimal medical therapy and supervised exercise, or for critical limb-threatening ischemia. 2 Revascularization solely to prevent progression to critical limb ischemia is not indicated. 2